Welcome to our dedicated page for Coeptis Therapeutics news (Ticker: COEP), a resource for investors and traders seeking the latest updates and insights on Coeptis Therapeutics stock.
News and press releases about Coeptis Therapeutics Holdings Inc. (Nasdaq: COEP) highlight its evolution as a biopharmaceutical and technology company, its cell therapy platforms, and its corporate transactions. Company announcements describe Coeptis as operating biopharmaceutical divisions focused on cell therapy platforms for cancer, autoimmune, and infectious diseases, alongside a Technology Division built around AI-powered marketing software and robotic process automation tools acquired from NexGenAI Solutions Group.
Recent news has emphasized developments in Coeptis’ pipeline and partnerships. The company has reported securing exclusive worldwide development and commercialization rights to the GEAR Cell Therapy Platform and forming GEAR Therapeutics, Inc. to advance GEAR-modified NK cells for a broad range of cancers. SNAP Biosciences, a majority-owned subsidiary, has announced a licensing agreement with Monarch Therapeutics to enhance the SNAP-CAR NK cell therapy platform using small-molecule adaptor technology.
Coverage also includes updates on Coeptis’ hybrid business model and technology initiatives. Articles describe how the NexGenAI platform contributes revenue while the company advances its cell therapy research, and how a co-working technology hub in India supports AI, blockchain, and digital transformation projects for the NexGenAI Affiliates Group.
Another key theme in recent news is corporate strategy and capital structure. Coeptis has announced the extinguishment of a convertible note with YA II PN, Ltd, and multiple releases detail a proposed merger with Z Squared Inc., a Dogecoin-focused digital asset mining company. These items cover the filing and effectiveness of a Form S-4 registration statement, the planned spin-out of biopharmaceutical operations, and the intention for the combined company to focus on digital asset mining. Investors and observers can use this news stream to follow Coeptis’ biopharmaceutical progress, technology partnerships, financing actions, and the status of its planned merger with Z Squared.
Coeptis (Nasdaq: COEP) announced that its shareholders approved the previously announced merger with Z Squared Inc.; the shareholder vote occurred on January 30, 2026. In connection with the combination, Z Squared is expected to become a wholly owned subsidiary of Coeptis upon closing. The transaction remains subject to satisfaction of remaining closing conditions. Additional vote details and merger information are available in the company’s Form 8-K filed with the SEC and on the company investor website.
Coeptis Therapeutics (Nasdaq: COEP) announced that its Form S-4 (File No. 333-288329) relating to the proposed merger with Z Squared has been declared effective by the SEC.
The company said it will begin mailing the definitive proxy statement/prospectus to stockholders of record as of January 2, 2026, and will hold an Annual/Special Stockholder Meeting on January 30, 2026. Notice of the meeting will be mailed on or about January 7, 2026.
Coeptis noted it has submitted an application to list the combined company’s common stock on Nasdaq, but approval is not assured; if not approved the combined company would trade on OTC Markets after the Transaction.
Coeptis Therapeutics (NASDAQ: COEP) is demonstrating a successful dual-track business model that combines revenue generation with biotech innovation. The company reported Q2 2025 revenue of $200,681 while advancing its GEAR Cell Therapy Platform for cancer treatment. Their cash position significantly improved from $532,885 at end-2024 to $1,996,726 by June 2025.
The company secured exclusive worldwide rights to the GEAR Cell Therapy Platform from Karolinska Institutet in March 2025 and completed a $10 million Series A preferred stock offering in February 2025, followed by a private placement targeting $2.5-$5 million in July. Operating expenses increased to $4.67 million in Q2 2025 from $2.83 million year-over-year due to restructuring costs.
Coeptis Therapeutics Holdings (NASDAQ:COEP), a next-gen technology and biopharmaceutical company, has announced the extinguishment of its convertible note with YA II PN, Ltd (Yorkville). The note, which was dated January 16, 2025, represented the company's outstanding debt obligations to Yorkville.
CEO David Mehalick emphasized that clearing this debt strengthens the company's capital structure. The company views this debt clearance as strategically important as it plans to expand into cryptocurrency operations.
Coeptis Therapeutics Holdings (NASDAQ:COEP), a next-gen technology and biopharmaceutical company, has filed a registration statement on Form S-4 with the Securities and Exchange Commission (SEC). The filing relates to the company's previously announced proposed merger with Z Squared Inc.
The Form S-4 includes a preliminary proxy statement/prospectus regarding the proposed transaction. The registration statement is currently pending effectiveness and the information contained within remains subject to change.
SNAP Biosciences, a subsidiary of Coeptis Therapeutics Holdings (NASDAQ: COEP), has entered into a licensing agreement with Monarch Therapeutics to enhance their SNAP-CAR NK cell therapy platform in oncology. The agreement provides SNAP Biosciences access to Monarch's small molecule adaptor technology, which enables SNAP-CAR cells to be directed by small molecule-based adaptors.
The integration of Monarch's technology with SNAP-CAR NK cells allows for simultaneous targeting of multiple tumor antigens and real-time activity modulation, addressing challenges like tumor heterogeneity and antigen escape. Under the agreement terms, Monarch will receive an upfront payment, potential development milestone payments, and royalties on net sales.
NUBURU (NYSE: BURU) has filed a $100 million SEC Registration Statement to support its strategic acquisition plans and blue laser technology business relaunch. The company is awaiting Italian government 'Golden Power' approval to acquire a defense and security business hub, which includes a DefenseTech Business and a SaaS Business component.
The acquisitions are expected to generate over $50 million in revenue for 2025, pending U.S. GAAP accounting and closing date. The regulatory assessment under Italy's \"golden power\" review is anticipated to conclude by the end of June. Additionally, NUBURU is implementing a Transformation Plan focusing on AI and robotics adoption through a partnership with COEPTIS' NexGenAI Affiliates Network.
Coeptis Therapeutics Holdings (NASDAQ: COEP) has announced a definitive merger agreement with Z Squared Inc., a Dogecoin mining company. The merger will transform Coeptis into the largest publicly-traded, Dogecoin-focused mining company globally. Under the agreement, Z Squared will become a wholly-owned subsidiary of Coeptis in exchange for 9,000 U.S. based dogecoin mining machines.
The transaction, expected to close in Q3 2025, will involve Coeptis spinning out its biopharmaceutical operations while maintaining its technology operations. Post-merger, the company will be rebranded as Z Squared, Inc. and continue listing on Nasdaq. The combined entity will focus on mining Dogecoin (DOGE), which currently has a market cap exceeding $20B.
The new leadership team will include David Halabu as CEO and Michelle Burke as COO, while current Coeptis CEO Dave Mehalick will exit the Board upon closing. The merger is subject to shareholder approval, regulatory clearances, and continued Nasdaq listing requirements.
COEPTIS (NASDAQ: COEP) has announced a strategic partnership with NexGenAI Solutions Group to establish a new co-working technology hub in India, operated by Ishvara Tech Consulting LLP. The facility will focus on advancing AI, blockchain technologies, digital transformation, and robotic solutions for defense and security.
The hub features a 60-seat capacity (expandable to 100) and includes executive cabins, conference rooms, and modern amenities. This expansion follows COEPTIS' recent acquisition of the NexGenAI Affiliates Network platform and new contracts totaling $2.3 million, including a $600,000 deal with NUBURU.
Key initiatives include:
- Research & Development
- AI Marketing Strategy Execution
- Crypto Strategy Execution & blockchain applications
- Product & Service Expansion
- Development and integration of the NXG Token
NUBURU (NYSE: BURU) announces a strategic corporate update focused on two key business lines. The company is revitalizing its blue-laser technology business unit through a new strategic plan targeting defense sector applications, marked by a recent Joint-Pursuit Agreement.
The company is finalizing the acquisition of a Defense & Security Hub, expected to generate over $50 million in 2025 revenue, subject to approvals. This hub will deliver defense products and security solutions through a SaaS model.
As part of its Transformation Plan, NUBURU has formed a strategic partnership with COEPTIS' NexGenAI Affiliates Network (NASDAQ: COEP) for AI and robotics solutions. The company has also invested in Supply@ME Capital Plc (LON:SYME), a fintech platform for inventory monetization. NUBURU has eliminated 100% of its long-term debt and is finalizing remaining payables with a strategic funding partner.